Table 3.
Comparison of Baseline Patient Characteristics in aPTT Controls Versus Anti-Xa Cohort.a
| Clinical Characteristic | aPTT | Anti-Xa | P Value |
|---|---|---|---|
| Number of patients | 100 | 101 | |
| Age, years | 64.4 ± 14.2 | 65.5 ± 13.6 | .59 |
| Race | .43 | ||
| White | 89 (89) | 94 (93.1) | |
| Black | 7 (7) | 4 (4) | |
| Asian | 0 (0) | 1 (1) | |
| Unknown | 4 (4) | 2 (2) | |
| Height, cm | 171.8 ± 11.3 | 170.5 ± 10.1 | .40 |
| Weight, kg | 89.7 ± 27.1 | 87.3 ± 21.3 | .49 |
| BMI, kg/m2 | 30.3 ± 8.3 | 30.1 ± 7.3 | .89 |
| Kidney dysfunction, GFR < 60 mL/min | 44 (44) | 43 (42.6) | .88 |
| Concurrent medications | |||
| ASA | 80 (80) | 71 (70.3) | .14 |
| P2Y12 inhibitor | 32 (32) | 31 (30.7) | .88 |
| GP IIb/IIIa inhibitor | 1 (1) | 1 (1) | 1.00 |
| Warfarin | 46 (46) | 41 (40.6) | .47 |
| Selective Xa inhibitor | 0 (0) | 1 (1) | 1.00 |
| DTI | 0 (0) | 1 (1) | 1.00 |
| Heparin nomogram | .70 | ||
| Afib/Post-Op | 40 (40) | 47 (46.5) | |
| UA/NSTEMI | 36 (36) | 29 (28.7) | |
| DVT/PE | 22 (22) | 23 (22.8) | |
| Stroke/EP/VAD/high-risk bleed | 2 (2) | 2 (2) | |
| Bolus | 39 (39) | 47 (46.5) | .31 |
Abbreviations: Afib, atrial fibrillation; aPTT, activated partial thromboplastin time; ASA, aspirin; BMI, body mass index; DVT/PE, deep vein thrombosis/pulmonary embolism; DTI, direct thrombin inhibitor; EP, electrophysiology; GFR, glomerular filtration rate; GP, glycoprotein; Post-Op, postoperative; UA/NSTEMI, unstable angina/non-ST-segment elevation myocardial infarction; VAD, ventricular assist device.
aContinuous data are represented as mean (standard deviation) or median (range). Categorical data are expressed as n (%).